Novartis, like many generic drugmakers, was forced to pull copies of generic Zantac off shelves late last year after a carcinogen scare shocked the industry. Now, it's once again pulling products off shelves—and this time, it's two branded drugs whose packaging has proved hazardous to children.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,